10-K: SAB Biotherapeutics Reports Positive Phase 1 Results for Type 1 Diabetes Therapy SAB-142; Plans Phase 2b Trial

SAB Biotherapeutics announces positive Phase 1 clinical results for SAB-142, a potential disease-modifying therapy for Type 1 Diabetes, and plans to advance to a Phase 2b trial in 2025.

Summary

• SAB Biotherapeutics, a clinical-stage biopharmaceutical company, is focused on developing human polyclonal immunotherapeutic antibodies (hIgG) for immunology disorders.
• The company's lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) aimed at preventing or delaying the progression of Type 1 Diabetes (T1D).
• SAB-142 received Investigational New Drug (IND) clearance from the FDA in May 2024 and announced positive topline data from its Phase 1 clinical trial in January 2025.
• The company plans to initiate a Phase 2b clinical trial called the SAFEGUARD study in mid-2025 to evaluate SAB-142 in adult and pediatric patients with new-onset T1D.
• The Phase 1 clinical trial of SAB-142 demonstrated a favorable safety profile and sustained immunomodulation, analogous to rabbit ATG, across multiple parameters correlative to C-peptide preservation.
• The company's proprietary production platform allows for the generation of targeted hIgG without the need for human donors or plasma.
• SAB Biotherapeutics operates two plasma fractionation and purification facilities in Sioux Falls, South Dakota.
• The company faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, including Sanofi S.A., Sana Biotechnology, and others.
• As of March 21, 2025, the company had 63 full-time employees, with 37 in research and development, 9 in clinical activities, and 17 in general and administrative roles.
• The company's independent registered public accounting firm has included an explanatory paragraph relating to the company's ability to continue as a going concern in its report on the audited financial statements.
• The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant on June 30, 2024, was $19,539,415.
• The number of shares of the registrant's common stock outstanding as of March 21, 2025 was 9,288,868.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. Positive clinical trial results are offset by financial losses and a going concern warning.

Positives

• Positive topline Phase 1 clinical results for SAB-142, showing a favorable safety profile and sustained immunomodulation.
• Advancement of SAB-142 into a Phase 2b trial, indicating progress in the clinical development program.
• Proprietary production platform allows for targeted hIgG generation without human plasma donors, providing a competitive advantage.
• Established regulatory pathway with the FDA, MHRA, and TGA, streamlining the approval process.
• Zero serum sickness and zero immunogenicity observed in the Phase 1 clinical trial of SAB-142, supporting its potential for safe and reliable re-dosing.
• The company has a significant number of patents issued or pending applications.

Negatives

• The company has incurred significant losses since its inception and may continue to incur losses for the foreseeable future.
• The company's independent registered public accounting firm has included an explanatory paragraph relating to the company's ability to continue as a going concern in its report on the audited financial statements.
• The successful development of pharmaceutical products is highly uncertain.
• All of the company's product candidates are in preclinical or clinical development.
• The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable.
• The company is limited in its ability to manufacture pharmaceutical products.
• The company has no sales and marketing experience.
• The company is an emerging growth company, and its election to comply with the reduced disclosure requirements as a public company may make its common stock less attractive to investors.
• The company's warrants are accounted for as liabilities and changes in value of the warrants could have a material effect on its financial results.
• The company's business, financial condition, and results of operations may fluctuate on a quarterly and annual basis, which may result in a decline in its stock price if such fluctuations result in a failure to meet the expectations of securities analysts or investors.

Risks

• The company's ability to continue as a going concern is dependent on its ability to obtain adequate financing in the future.
• Clinical trials may fail to demonstrate the safety and efficacy of product candidates.
• Regulatory approval for the genetic modification of animals requires a New Animal Drug Application, which can be lengthy and expensive.
• The company may encounter difficulties enrolling patients in clinical trials.
• The company relies on third parties to perform some of its research and preclinical studies, and it plans to rely on third parties to conduct its clinical trials.
• The company intends to rely on third parties to produce commercial supplies of its product candidates.
• The company is subject to manufacturing risks that could substantially increase the costs and limit supply of product candidates or prevent it from achieving a commercially viable production process.
• The company operates in a highly competitive industry.
• The company is subject to stringent environmental regulation and potentially subject to environmental litigation, proceedings, and investigations.
• The company's success depends on its ability to maintain the proprietary nature of its technology.
• Third parties may claim the company infringes their intellectual property rights.
• The company may become involved in litigation to protect or enforce its patents or the patents of its collaborators or licensors, which could be expensive and time-consuming.
• If patent laws or the interpretation of patent laws change, the company's competitors may be able to develop and commercialize its discoveries.
• The market price of the company's securities may be volatile, which could cause the value of any investment in its securities to decline.
• There can be no assurance that the company will be able to comply with the continued listing standards of Nasdaq.
• Changes in legislation in U.S. and foreign taxation of international business activities or the adoption of other tax reform policies, as well as the application of such laws, could adversely impact the company's financial position and operating results.
• Tariffs could adversely affect the company's business and financial results.
• Cyber-attacks or other failures in the company's telecommunications or information technology systems, or those of its collaborators, CROs, third-party logistics providers, distributors or other contractors or consultants, could result in information theft, data corruption and significant disruption of its business operations.

Future Outlook

The company plans to advance SAB-142 into a Phase 2b trial in 2025 and expects to continue incurring substantial research and development expenses as it conducts discovery research and works on its indications. The company anticipates that general and administrative expenses will rise as it expands its workforce and invests in the advancement of its lead therapeutic candidate in preparation for potential commercialization.

Industry Context

The biopharmaceutical industry is highly competitive and subject to rapid technological change. The company faces competition from multiple sources, including major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic research institutions, governmental agencies, and public and private research institutions worldwide.

Comparison to Industry Standards

• The document mentions several competitors including Sanofi S.A., Sana Biotechnology, Imcyse, vTv Therapeutics, IM Therapeutics, Sernova, and Biomea Fusion.
• Sanofi S.A. is a major pharmaceutical company that markets Thymoglobulin TM and has acquired Tzield TM, a monoclonal antibody for T1D.
• Pfizer markets Atgam TM, an animal-derived polyclonal biologic for T1D.
• The document highlights that SAB-142 has advantages over rabbit ATG, which shows therapeutic promise but its heterologous nature and high immunogenicity are problematic given adverse events that could inhibit long term disease modification and redosing.

Management Changes

Legal Proceedings

• The company is not currently a party to any material litigation, nor are they aware of any pending or threatened litigation against them that they believe would materially affect their business, operating results, financial condition, or cash flows.

Stakeholder Impact

• The company's ability to continue as a going concern impacts stakeholders including shareholders, employees, customers, suppliers, and creditors.
• Positive clinical trial results and advancement of SAB-142 have a positive impact on patients with Type 1 Diabetes.
• The company's success in developing and commercializing its product candidates will impact its ability to attract and retain key scientific, medical, commercial, or management personnel.

Next Steps

• Initiate a global Phase 2b study, SAFEGUARD, in mid-2025 to evaluate SAB-142 in new-onset pediatric, adolescent, and adult Stage 3 T1D patients.
• Following the trials in Stage 3, progress into clinical trials in Stage 2 patients.
• Continue to develop intellectual property and specifically targeted hIgG to multiple disease indications.

Key Dates

Keywords

SAB-142, Type 1 Diabetes, T1D, clinical trial, immunotherapy, hIgG, antibodies, biopharmaceutical, FDA, regulatory approval, manufacturing, patent, intellectual property, risk factors, financial results